EFPIA - NEWSLETTER

Trouble reading this email? View it in your browser


		EFPIA Newsletter 24 November 2022

Podcasts

What would be the impact of a TRIPS waiver extension?
21 November 2022

Industry has shown its commitment to work with partners in order to ensure that vaccines and therapies reach patients... Read more

Blogs

How to improve patient access to novel antibiotics in Europe: Recommendations for policies...
24 November 2022 - Sophie Noya

A new report seeks to highlight the significant barriers existing at the national level - related to value-assessment... Read more

What would be the impact of a waiver extension
23 November 2022 - Hugh Pullen

Waiving IP would not only attempt to solve a problem that does not exist. It would send a clear message to companies... Read more

Medicine shortages: EFPIA proposals for action
22 November 2022 - Marco Farinelli

9 concrete proposals underpinned by 5 principles to help protect patients across Europe from the impact of shortages... Read more

How research pharmaceutical companies are contributing towards tackling global warming
22 November 2022 - Kirsty Reid - Reinhold Maeck

Understanding the relationship between people, health and the environment is critical to ensuring the pharmaceutical... Read more

How can we reverse Europe's declining trend in medical innovation?

Dhaval Patel, Executive Vice President and Chief Scientific Officer, UCB, and Nathalie Moll, Director General, EFPIA, presented the key findings of the "Factors affecting the location of biopharmaceutical investments" report at the 2022 European Business Summit.

Watch the recording of the exclusive interview here.

Events

DIA Health Technology Assessment (HTA) Forum
28 November 2022 ( Brussels, Belgium)

... Read more

European Health Summit 2022
08 December 2022 (Egmont Palace, Brussels)

Join us on 8th December! Read more

How can we reduce premature and preventable deaths caused by cardiovascular diseases and diabetes?...
12 December 2022 (Brussels)

... Read more

ACCELERATE 2023 Annual Conference
09 February 2023 (Brussels & online)

All sessions, including Breakout Sessions, will be available for both in-person and online participants. Read more

The Power of Innovation

Innovative treatments for Rheumatoid Arthritis reduce pain and improve quality of life. For patients, it means the chance to go to work: 132 million working days are gained per year through reducing absenteeism.

What we are reading

Europe can and must remain a globally competitive region for medical innovation
On 24 November 2022 (Gold News)

Nathalie Moll's interview with Cyprus' business magazine. Read more

As WTO Considers Patent Waiver on COVID Treatments, Some Say it is Too Late
On 24 November 2022 (Health Policy Watch)

Recent Airfinity data show that inequality in access is not a pricing issue. Read more

EU health data space impossible without trust, Commissioner says
On 16 November 2022 (Euractiv)

The Commission aims to have the European health data space up and running in 2025. Read more

About the EFPIA newsletter

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

Tel: +32 (0)2 626 25 55
E-mail:Communications@efpia.eu